Sunshine Biopharma Incorporated (SBFM)

Sunshine Biopharma's stock price has significantly declined over the past six months, decreasing by 56.90% from January 6, 2025, to January 2, 2026, and by 57.64% over the past year as of April 25, 2024. The company underwent a 1-for-100 reverse split on April 17, 2024. The company reported an 18% increase in revenue to $8.9 million in Q1 2025, leading to a 13.6% gain in SBFM shares. In Q3 2025, the company reported an EPS of -$0.19, missing analyst estimates. Product launches in Canada in October 2025 positively impacted the stock.

Information regarding the demand seasonality for Sunshine Biopharma's specific products and services is limited. Analysis of the stock's seasonal chart suggests a "Buy Date of November 13 and a Sell Date of February 6" has resulted in an average return of 84.33% above the S&P 500 Total Return Index. This seasonal timeframe has shown positive results in 2 out of 4 periods and correlates poorly with the broader Healthcare sector's seasonal strength.

Sunshine Biopharma, Inc. is a pharmaceutical company focused on researching, developing, and commercializing life-saving medicines, particularly in oncology and antivirals. The company also provides generic prescription drugs and over-the-counter supplements. Its major products include SBFM-PL4 for SARS coronavirus infections, Adva-27a for pancreatic cancer, and K1.1 mRNA for liver cancer. Through Nora Pharma Inc., it offers about 70 generic prescription drugs in Canada. The company also develops and sells OTC supplements like Essential 9, Essential Calcium-Vitamin D, L-Citrulline, and Taurine products.

Sunshine Biopharma operates and conducts research in the United States and Canada. The company's headquarters are in Fort Lauderdale, Florida, with a satellite office in Montreal, Quebec, Canada. In December 2023, the company announced the relocation of its principal office to New York City.

Sunshine Biopharma's brand reputation has been influenced by its drug development programs and product launches. The regulatory clearance and commercial launch of generic prescription drugs in Canada have likely contributed to a favorable perception of the company's progress and market expansion, enhancing its standing.

Sunshine Biopharma's ownership is distributed among institutional shareholders, insiders, and retail investors. Institutional shareholders hold between 4.61% and 41.98% of the stock. Malek Chamoun is the largest individual shareholder, owning 75.42% of the company. Retail investors hold approximately 13.76% of the company. Shareholders have experienced substantial dilution, with total shares outstanding growing by 145.3%.